Engineering Theranostic Nanovehicles to Target Cerebrovascular Amyloid

Targeted theranostic nanovehicles are capable of targeting cerebrovascular amyloid associated with Alzheimer’s Disease and serving as early diagnostic and therapeutic agents across multiple imaging modalities. Assessed in animal models at 21.1 T, these nanovehicles were loaded with gadolinium-based magnetic resonance imaging (MRI), iodine-based single photon emission computerized tomography (SPECT) or fluorescent contrast agents as well as anti-inflammatory and anti-amyloidogenic pharmaceuticals to demonstrate targeted enhancement and treatment in cerebral amyloid angiopathy.